Navigation Links
Study Published in Clinical Cancer Research Confirms Potential Of Peregrine's Bavituximab Combined With Radiation In Lung Cancer
Date:9/4/2007

- Bavituximab Equivalent Combined With Radiation Reduced Tumor Growth by

80% in Preclinical Lung Cancer Model - - Findings Confirm Key Aspects of Bavituximab's Mechanism of Action in

Combination with Radiation Therapy - - Results Further Support Future Clinical Trials Testing Bavituximab in

Combination With Radiation Therapy -

TUSTIN, Calif., Sept. 4 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing targeted monoclonal antibodies for the treatment of cancer and hepatitis C virus infection, today reported that researchers have published a new study in a lung cancer model showing that the combination of a mouse equivalent of bavituximab and radiation is significantly more effective in reducing tumor growth than either therapy alone. The study was published in the September 1 issue of Clinical Cancer Research. Bavituximab, Peregrine's lead anti-phosphatidylserine (anti-PS) immunotherapy, is currently in clinical trials for the treatment of solid tumors including lung cancer.

"This new publication further supports the concept that radiation therapy and bavituximab may work synergistically to treat solid tumors." said Steven W. King, president and CEO of Peregrine. "We are particularly pleased to see these positive results in a model of radiation resistant lung cancer, by far the leading cause of U.S. cancer deaths. This is the latest in a series of preclinical studies that have demonstrated the potential of either radiation or chemotherapy to enhance bavituximab's anti-tumor effects. We look forward to evaluating a combination of bavituximab plus radiation therapy i
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Antibodies for Studying NMDA Receptor Protein Expression and Synapse-Specific Immunolabeling
2. Optimizing Transfection Conditions for Studying Signal Transduction Pathways
3. Enzyme Immunoassay for Studying Intracellular Levels of cAMP
4. RT-PCR Primers for the Study of Apoptosis
5. A Comparison Study of Lipid Tranfection Reagents in A549, NIH 3T3 and COS-7 Cell Lines
6. New Reporter Plasmids for Studying Interferon-Stimulated Signal Transduction Pathways
7. New Fusion Trans-Activator Plasmids for Studying Signal Transduction Pathways
8. Medical College receives $377K to study brain disease
9. Kauffman study shows consistent entrepreneurial growth
10. Study affirms information technology-productivity link
11. Deltanoid Pharmaceuticals begins phase II osteoporosis study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... LA JOLLA, Calif. , July 30, 2014 /PRNewswire/ ... RGLS ), a biopharmaceutical company leading the discovery and ... it will report financial results and highlights for the ... 2014, after the U.S. financial markets close. ... on Wednesday, August 6, 2014, at 5:00 pm Eastern ...
(Date:7/30/2014)... and PARIS , July 30, ... (EURONEXT: SAN and NYSE: SNY) today announced that the ... Administration (FDA) rare pediatric disease priority review voucher in ... alirocumab.  The priority review voucher entitles the holder to ... an expedited 6-month review from the filing date instead ...
(Date:7/30/2014)... 30, 2014 W. R. Grace ... of the REVELERIS® Prep purification system , ... chromatographers, and other researchers to perform both flash ... unit. , With the REVELERIS® Prep purification system, ... chromatography modes with a simple touch of the ...
(Date:7/30/2014)... , July 30, 2014  Decision Resources ... and medical directors in the United ... of biosimilar market penetration will be the level ... (MCOs) and the expected lower cost to patients. ... biosimilars that meet their pricing expectations in order ...
Breaking Biology Technology:Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 2Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 4Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 5Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 6Grace Launches New REVELERIS® Prep Purification System 2Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 2Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 3
... The National Science Foundation,(NSF) has awarded Loma ... of $593,978 to lead a consortium in developing ... universities. Barry L. Taylor, Ph.D., Professor of Microbiology,and ... Affairs,will lead the project with Rohit Shukla, CEO ...
... - Oncothyreon Inc.,(Nasdaq: ONTY ) (TSX:ONY) announced ... studies of PX-12 and preclinical studies of,PX-866 will ... American Association,for Cancer Research (AACR) in San Diego ... a Phase 1 clinical trial of PX-478,in patients ...
... Biopure,Corporation (Nasdaq: BPUR ) announced today that ... its independent auditor., The audit committee of ... review of audit firms that had expertise with ... in Boston, Massachusetts, Vitale, Caturano & Company, Ltd. ...
Cached Biology Technology:Loma Linda University Partners With Larta Institute for Technology Marketing Program 2Oncothyreon announces data from multiple small molecule programs to be presented at American Association of Cancer Research Annual Meeting 2Oncothyreon announces data from multiple small molecule programs to be presented at American Association of Cancer Research Annual Meeting 3
(Date:7/30/2014)... Lewis Carroll,s Through the Looking Glass, collaborators from ... Singapore improved a 35-year-old ecology model to better ... of years. , The new model, called a ... Queen Effect," an evolutionary hypothesis introduced by Lee ... organisms must constantly increase their fitness (or ability ...
(Date:7/30/2014)... A deep-sea octopus protected and tended her eggs until ... published July 30, 2014 in the open-access journal ... Aquarium Research Institute and colleagues. , Octopuses typically have ... females protect and take care of their fertilized eggs ... eggs for 1 to 3 months, but little is ...
(Date:7/30/2014)... announced today that David L. Kaplan, Ph.D., will head ... Engineering as editor-in-chief. With the first issue slated ... feature high-quality research in the rapidly burgeoning field of ... that interact with living or biological systems. , "This ... growth in the field of biomaterials over the past ...
Breaking Biology News(10 mins):Classic Lewis Carroll character inspires new ecological model 2Classic Lewis Carroll character inspires new ecological model 3Deep-sea octopus has longest-known egg-brooding period 2ACS Biomaterials Science & Engineering: Brand-new journal launches in 2015, names editor 2
... U.S. Department of,Homeland Security (DHS) announced today ... international visitors arriving at Boston,Logan International Airport ... department,s,upgrade from two- to 10-fingerprint collection to ... accurately and efficiently,establishing and verifying visitors, identities., ...
... About the Ocean Sciences Meeting News Media Registration ... 4 February 2008 Abstracts and Schedule Available Online Who,s ... This years meeting will offer a wealth of new ... it is found, from mountain peaks to deep ocean ...
... bring a combination of individual scientific skills, expertise ... these offer the opportunity to build a highly ... address the urgent need for bringing new antibiotic ... antibiotics and other antimicrobial agents have saved millions ...
Cached Biology News:DHS Begins Collecting 10 Fingerprints From International Visitors at Boston Logan International Airport 2Media advisory -- 2008 Ocean Sciences Meeting 2Media advisory -- 2008 Ocean Sciences Meeting 3Media advisory -- 2008 Ocean Sciences Meeting 4Unique fungal collection could hold key to future antibiotics 2Unique fungal collection could hold key to future antibiotics 3
... is an inhibitor of ... concentration of inhibitor required ... must be determined empirically ... micromolar inhibitor is sufficient ...
Human RELT/TNFRSF19L Affinity Purified Polyclonal Ab...
Mouse NOV/CCN3 Affinity Purified Polyclonal Ab...
HiTrap NHS-activated HP, 1 x 5 ml. Category: Chromatography Systems & Accessories, Systems....
Biology Products: